Avantor Inc. (AVTR) Stock Forecast & Price Target

Avantor is viewed positively because its turnaround is increasingly visible in the core Laboratory Solutions business, where Q2 delivered 1.7% organic growth, a 10.2% operating margin, and signs that share gains from better service, e-commerce, and pricing are taking hold. Bioscience Production also looks positioned to improve, with double-digit order growth and a 1.1x book-to-bill pointing to a return to growth in 2H, while raised FY26 organic revenue guidance to -0.5% to +0.5% and EPS guidance to $0.80-$0.83 show execution is translating into better fundamentals. The positive outlook is further supported by improving end markets, including firmer large-pharma and biotech demand, improved biotech funding, stabilization in NIH support, and a management plan that keeps leverage at or below 3x while targeting steady margin and cash flow progress.

Avantor is challenged by a persistently weak growth profile, as 2Q26 organic revenue still declined 0.4% and VWR revenue was (-4%) in 2025, underscoring that the recent beat is coming from Revival actions and improving pharma/biotech activity rather than a broad end-market inflection. Its Bioscience and MedTech business remains structurally slower than bioprocess peers, with process chemicals and fluid handling only partially offsetting declines in research, specialty chemicals, and other categories, while competitive pressure from Thermo Fisher continues to threaten share. Profitability and cash generation also look fragile, with gross margin down ~120 bps, EBITDA margin down ~160 bps, adjusted net leverage at 3.3x, and 2026 free cash flow guidance of $500M-$550M still looking difficult to achieve.